{"pub": "metro", "url": "https://metro.co.uk/2019/10/05/new-drug-blocks-cancers-escape-route-from-chemotherapy-10866352", "downloaded_at": "2019-10-05 12:34:06.646788+00:00", "title": "New drug blocks cancer\u2019s \u2018escape route from chemotherapy\u2019", "language": "en", "text": "A new drug which forces cancer cells through cell division too quickly is being trialled (Picture: CIPhotos)\n\nA new drug which reinvigorates the body\u2019s response to chemotherapy could become a new weapon in the war against cancer.\n\nExperts at London\u2019s Institute of Cancer Research have begun clinical trials with BOS172722, which forces cancer cells through cell division too quickly, killing them off.\n\nNow it\u2019s hoped the new drug could also be used to tackle other variations of the killer disease.\n\nBOS172722 works by blocking, MPS1, a molecule which plays a key role in cell division.\n\nThe molecule is involved in the distribution of chromosomes, ensuring they are evenly shared.\n\nBy blocking the molecule, the process is sped up meaning cancer cells have the wrong number of chromosomes and die.\n\nResearchers also discovered that fast-dividing cells, from breast, ovarian and lung cancers, were especially sensitive to the new drug.\n\nResearchers have found that cells from breast cancer are especially sensitive to BOS172722\n\n(Picture: PicturePartners)\n\nProfessor Spiros Linardopoulos, professor of cancer biology and therapeutics at The Institute of Cancer Research, London, led the study and said he is looking forward to the results.\n\nAdvertisement\n\nAdvertisement\n\nHe explained: \u2018The drug works especially well in combination with chemotherapy in triple negative breast cancer cells \u2013 the deadliest form of breast cancer for which there are few successful treatments.\n\n\u2018Crucially, the combination is anticipated to be effective in cancer patients that have already become resistant to chemotherapy alone and has the potential to become a much-needed extra treatment option that could extend the lives of patients.\u2019\n\nProfessor Rajesh Chopra, director of cancer therapeutics in the new centre for Cancer Drug Discovery, said he was thrilled.\n\nThe new drug works well in combination with triple negative breast cancer cells\n\n(Picture: Lester Lefkowitz)\n\nHe commented: \u2018Cancer\u2019s ability to evolve and become drug resistant is the cause of the vast majority of deaths from the disease.\n\n\u2018We plan to counter that ability with the world\u2019s first \u2018Darwinian\u2019 drug discovery programme dedicated to creating a new generation of anti-evolution treatments.\n\n\u2018Our new MPS1 inhibitor is a great example of a drug that seeks to outsmart cancer by blocking off a key evolutionary escape route, and in doing so we believe it can breathe new life into a chemotherapy that had ceased to be effective.\u2019\n\nThe new study is published in the journal Molecular Cancer Therapeutics.\n\nGot a story for Metro.co.uk? Get in touch with our news team by emailing us at webnews@metro.co.uk. For more stories like this, check our news page.", "description": "A new evolution-busting drug could give a boost to thousands of cancer patients", "authors": ["Tim Green"], "top_image": "https://i2.wp.com/metro.co.uk/wp-content/uploads/2019/10/PRI_88468099_1570274507.jpg?quality=90&strip=all&w=1200&h=630&crop=1&zoom=1&ssl=1", "published_at": "2019-10-05"}